Guest guest Posted May 17, 2008 Report Share Posted May 17, 2008 Thanks , that was relevant. I would be afraid of playing Russian Roulette, even though some patients were doing well without it. The end of the article does not advocate for stopping Gleevec, probably because there is still not enough evidence and good calibrations from the different instruments used not all being equal. That seems to me to be a small cohort of patients in this study. Quoting from the article: " As shown in our study, 50% of patients in complete molecular remission for more than 2 years remain in molecular remission after 18 months of follow-up. However, we do not widely recommend imatinib discontinuation at the present time. We have initiated a large prospective study to better characterize patients with undetectable BCR-ABL. " I think that all the patients had minimal residual disease and for many of us, that is just not the case. For some this would make a strong case for not stopping any CML meds at this time. It was interesting to read, however, that the median age was 42 to 83. Wow, that's even past my age and I am older than dirt. LOL. This would make for a lively discussion. Peace and blessings, Lottie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.